header logo image


Page 1,001«..1020..1,0001,0011,0021,003..1,0101,020..»

GR8 Inspirations: Local man helps people manage their diabetes, change their lives – WFLA

July 5th, 2017 8:43 pm

TAMPA, Fla. (WFLA) Charles Mattocks found a way to take his message around the globe by creating an onlinedocu-series about his own struggles with diabetes called Reversed.

The series is about educating participants who are struggling with diabetes about how to better manage the disease.

Its taken me literally around the world. From India to the islands. I wanted to take my journey and see what it would be like if someone was just diagnosed with diabetes, said Mattocks.

Mattocks was getting national exposure as a celebrity chef when he was hit with the news that he had type 2 diabetes.

I used to think drinking ginger ale was good for you because it has ginger in it. I dont know what I was thinking. I was one of these guys, with all this chest and all of this stomach so thats when I knew I had to look in the mirror.

Looking into a mirror and through a camera lens, Mattocks quickly realized his journey was about connecting one-on-one with others.

That became a bigger journey as I saw people suffering, and I started to see people who were hurting. This is a killer, theres somebody in the hospital right now dying from a diabetes complication. Its the number one leading cause of amputation, its the number one leading cause of blindness. 80 percent of diabetes patients die from heart disease, so this is nothing to play with, said Mattocks.

The award-winning producer and bestselling author will host Reversed and will play a role in helping people hes met along his journey to change their diet, exercise and mindset about the disease. The series will feature experts such as diabetes educators, endocrinologist, therapists, nutritionist, and trainers.

There will also be surprise visits from celebrity guests who are also living with diabetes, to help encourage the contestants.

Its his mission to save those struggling with diabetes makes Charles Mattocks a Gr8 Inspiration.

STORIES OTHERS ARE CLICKING ON:

BACK TO TOP STORIES

Originally posted here:
GR8 Inspirations: Local man helps people manage their diabetes, change their lives - WFLA

Read More...

Personalized Medicine Summit Personalized Medicine …

July 5th, 2017 8:43 pm

Register Now for the Personalized Medicine Summit 2017

Sunday June 11th-Tuesday June 13th, 2017-The Summit will be held at the Life Sciences Institute, University of British Columbia, Vancouver, BC

The Personalized Medicine Initiative and partners are pleased to announce the 2nd Personalized Medicine Summit 2017, scheduled for June 11-13, 2017 at the University of British Columbia (UBC). This meeting follows on from the highly successful 1st Personalized Summit 2015 at UBC, which resulted in a consensus advisory document, the Roadmap for Bringing Personalized Medicine to British Columbians. The Summit will produce an updated Roadmap to assist government, the public and healthcare providers to implement personalized precision medicine to result in more efficient and effective healthcare.

The 2nd Summit will attract an internationally renowned faculty and will be of interest to clinicians, patient advocates, health care providers, academics and representatives from government and industry who are interested in the revolution in healthcare that is being enabled by personalized, molecularly-based medicine. We anticipate approximately 450 attendees.

The deliverable of the summit meeting will be an updated edition of our 2015 publication Roadmap for Bringing Personalized Medicine to British Columbians (see attached). This publication summarized the consensus arising from the Personalized Medicine Summit 2015 and made four major recommendations:

Contact:

the.summit@ubc.ca

Follow this link:
Personalized Medicine Summit Personalized Medicine ...

Read More...

We Just Got Two Steps Closer to Personalized Cancer Vaccines … – Mental Floss

July 5th, 2017 8:43 pm

Study by study, researchers are pushing ever closer toward identifying the gene variants to blame for inflammatory bowel disease (IBD). The latest and most promising findings were published in the journal Nature.

There are two forms of IBD: ulcerative colitis, which affects only the colon and is more common in women; and Crohn's disease, which can affect any part of the gastrointestinal tract and is slightly more common in men. Today, IBD affects between 1 and 1.3 million Americans, yet we understand very little about why it happens or why some groups of people are more susceptible than others.

It's possible and even likely, scientists say, that the root of the illness could lie in our genes. Previous studies have linked IBD to hundreds of different genetic variants, but that's as specific as they could get.

To take a closer look, researchers at three institutions collaborated to build a massive, high-resolution genetic map. They collected the genomes of 67,852 different people18,967 with Crohn's disease, 14,628 with ulcerative colitis, and 34,257 healthy people for a control groupand combed through, looking for variants unique to the folks with IBD.

Like previous researchers, they found plenty. But the new map was so detailed that its creators could zoom in further and further down, checking how likely it was that any given variant could actually cause the disease. From hundreds, they narrowed it down to just 18 variants, and had at least 95 percent certainty that these were the ones responsible. Some of these gene variants were related to processing amino acids; some seemed to interfere with healthy molecule binding; and some were tied to the switching on and off of immune or gut cells.

"We need to be careful in deciding when we are sure we have the right variant," first author Hailiang Huang, of Massachusetts General Hospital and the Broad Institute, said in a statement. "This new technique helps us to pinpoint which genetic variants are implicated in IBD with greater confidence."

The authors say that isolating IBD-related gene variants will help develop new drugs, and could someday even aid in personalized medicine by helping doctors identify which existing drugs will be most effective for their patients.

See the article here:
We Just Got Two Steps Closer to Personalized Cancer Vaccines ... - Mental Floss

Read More...

DNA testing – on the road to regenerative medicine – VatorNews

July 5th, 2017 8:42 pm

We recently had Dr. Craig Venter speak at our Splash Health 2017 event. Dr. Venter is the first person to sequence a human genome, simply put: the instructions and information about human development, physiology, and evolution. In his interview, he points out that 15 years ago, sequencing a human genome would have cost $100 million and take over nine months.

Oh how far weve come. Today, there are a number of companies helping us to analyze our genes, or basically our DNA, which make up genes, to understand our physiology. Advances in sequencing the human genome have been the foundation for this knowledge, and is ultimately paving the path toward personalized medicine - therapies that are personalized to a persons genetic code, and its cousin regenerative medicine - therapies that replace or enable damaged cells, organs to regenerate.

One company, Orig3n, is doing both. Boston-based Orig3n started out in 2014 collecting blood samples to conduct regenerative medicine studies, but later added in the ability to conduct DNA testing to learn more about a persons intelligence, or predisposition to learning languages, to knowing what vitamins theyre deficient in.

Its an interesting an unique funnel the company has created for itself on its way to solve big problems with regenerative medicine, which seems more in its infancy than DNA testing.

To that end, Orig3ns DNA testing business has taken off.

In order to be tested, you take a cotton swab and swab the inside of your cheek to collect DNA samples from the cells inside your mouth. Alternatively, one could spit in a tube, which is how 23andMe collects samples of DNA.

From there, Orig3n breaks down the cells to open up the DNA, which is inside the nucleus of the cell. The DNA is then purified and put into a genetic test panel. Your DNA is then analyzed against other DNA that have been collected and studied.

The analysis of the DNA is pretty standard. What differentiates its products, according to Robin Smith, Founder and CEO, is how the analysis is packaged and how quickly the results are turned around. The whole genome sequencing world has been around for 15 years and is fairly commoditized, said Smith. The same thing is happening with DNA detection. The biggest differentiator for Orig3n is that it delivers the data in ways that are understandable, said Smith.

For instance, on Orig3n, tests focus on an analysis of your skin to perfect your skincare routine, or about your strength and intelligence. Tests range from $20 to $100.

On Everlywell, you can take a DNA test to measure your sensitivity to foods. Or for around $239, it appears you can test to see if you have HIV, Herpes Type 2 and other sexual diseases.

On 23andMe, you can pay $199 to learn what proportion of your genes come from 31 populations worldwide, or what your genetic weight predisposes you to weigh vs an average and what are some healthy habits of people with your genetic makeup [though personally these habits seem to be good for anyone regardless of genetic makeup].

But for Orig3n, the DNA tests are just a good business while also a funnel to the bigger problem theyre trying to solve, and for which they recently raised $20 million for: Regenerative medicine.

Before offering the DNA tests, Orig3n was taking and continues to take blood samples, reprogramming cells to go back to a state three days prior. And from there, they can grow certain tissues. The purpose of Orig3n is to create cell therapies for various diseases and disorders.

In the next fives year, there will be real live therapies to repairing the degeneration of your eyes or performing some cardiac repair, Smith predicted. It feels like 1993 when I used a phone line to dial into the Internet, then seven years later we had the boom. We think regenerative medicine - getting your body to induce itself to rejuvenate parts that are broken - is where the Internet was in 1993.

Read more from the original source:
DNA testing - on the road to regenerative medicine - VatorNews

Read More...

After 50 Years, Equine Vet Not Ready for the Pasture – Southern Pines Pilot

July 5th, 2017 8:42 pm

Fresh from a teaching stint at Cornell Universitys veterinary school, moving to Southern Pines in 1971 made Fred McCashin feel a bit like a pioneer on the frontier of equine medicine.

Considering the manicured pastures of todays Southern Pines horse country and the miles of weathered post-and-rail fence lines in Moore Countys equestrian enclaves, that feeling is difficult to imagine.

But back then, much of the equestrian community here was seasonal fox hunters and harness racers and N.C. States College of Veterinary Medicine wouldnt be up and running for more than a decade.

McCashin, 76, recently attended the 50th reunion of his vet school class at the University of Pennsylvania. His Youngs Road practice, Carolina Equine Clinic, is celebrating its 40th year in business this month.

He came to North Carolina not to be a solo practitioner, but to direct the N.C. Veterinary Research Foundation. Established as a nonprofit by a group of veterinarians hoping to lay the foundation for a veterinary school, the facility is now the N.C. State Equine Research center on U.S. 1 north of Southern Pines.

Dr. Fred B. McCashin, shown here with Attaboy Roy, establshed the Carolina Equine Clinic in 1977. (Photo by Ted Fitzgerald/The Pilot)

Other opportunities were available: continuing to teach at Michigan State, or working as the staff veterinarian for the racing stable of a prominent French art dealer. At that point, though, hed had enough of difficult characters and the politics embroiled in academia. And the chance to fill a void for the states thriving horse business by performing surgery on a referral basis held its own fascination.

That was really sorely needed because there were very few veterinarians that would even attempt to do surgery in the state of North Carolina, said McCashin, who recalled his six years at the research foundation as nonstop work.

I could stay up all night operating on a case and you didnt have any time off the next day. It was like working on the prairies. It was a nice building and all, we had the facilities, but I was trying to get veterinarians in the field to come in with their cases and give me a hand, because sometimes you just cant do it all by yourself.

He opened Carolina Equine Clinic in 1977, working out of the barn on the property, then adding a clinic and lab building.

This is just a little modest thing, and I never made it any bigger, he said. I thought about having branches in Wilmington and other places where no one was doing surgeries, but I was busy enough here that I couldnt get away.

The clinic is strewn with relics from McCashins career in the form of calcified masses extracted from patients. One, the size of two fists, he found in 1982 while performing emergency colic surgery on a Morgan horse from a Raleigh farm before N.C. State started surgery.

In that particular case, McCashin rushed to the clinic on Halloween his children missed trick-or-treating that year not a moment too soon as he opened the patients abdomen to find it full of manure. Though that could have been a death sentence, the horse made a full recovery.

The owner was here and I said this is bad but I just took it and heaved it over the side and everything else looked reasonably clean, he recalled. The stone was there and it had ruptured his small colon. So we cleaned it up, took out the busted section and stuck it back together again and I said well just see how its going to go.

I dont ask the kids if they remember that, he said ruefully.

Its that kind of episode that remains so vivid to the longtime veterinarian that it might as well have happened yesterday. So too with the tough cases, solved through months of rehabilitation and sheer force of will like Jet Murmur, a Thoroughbred colt who broke his leg at around six months of age.

(Photo by Ted Fitzgerald/The Pilot)

In six months I think I had him on the table maybe seven times because the plates kept getting a little bit loose and Id go back in and tighten up the screws and put new screws in and kept altering the thing, McCashin said.

I remember taking him on a longe THIS IS CQ line up there on the hill and taking him through the woods and trotting him over logs and stuff. He was a long yearling by the time I sent him home and he ended up being a productive stallion.

McCashin developed a specific interest in orthopedic surgery as a student protg of Jacques Jenny, who invented the technique of bone plating inspired by Swiss compression equipment used to treat skiing-related fractures in humans. He remembers plating the first broken leg at Ohio State University while studying as a postdoctoral student there.

It was a fancy Quarter Horse filly by a stallion called Gunsmoke, he recalled. Its always fun if you happen to save the life of a horse thats in a line of really well-bred animals.

Appreciation of a good horse was in McCashins blood long before he became a veterinarian. His father, Arthur, was captain of the U.S. national show jumping team that won bronze at the 1952 Helsinki Olympics.

Growing up on a derelict polo field in New Jersey, McCashin and his older brother jockeyed their fathers steeplechase horses and jumpers. But it was on his fathers advice that he decided to forego a chance to ride in the Olympics himself.

Dad told me, If you had a horse and went to the Tokyo games in 64 and you win a gold medal, you put the gold medal and a dime on the counter and youll get a cup of coffee, McCashin said.

I did ride with the team for quite a while, just never competed, but I exercised some fancy, fancy jumpers. I was lucky to be on Ksar dEsprit and Fire One and San Lucas and horses that are in the history books.

Though he never got to ride in the Olympics, McCashin had a backstage pass to the 1976 games in Montreal as the official vet for the United States Equestrian Team and to the 1996 Atlanta Olympics as an officiating vet for the international governing body for equestrian sports known as the FEI matching the competition horses to their international passports and drug testing a random sample.

While he stepped back from work as a competition vet last year, retiring completely isnt in McCashins plans. Not that he hasnt considered it. But after 50 years, he isnt sure he knows how not to be a horse doctor.

For the last few years, the clinic has hired younger veterinarians to do the bulk of the everyday work driving around Moore and nearby counties vaccinating horses, performing dental work, and other preventive maintenance. McCashins current associate, Beth Susen, has a knack for tricky reproductive cases.

Several of the areas equine veterinarians initially built their reputations in Southern Pines while working as McCashins associate vets. Perhaps as notably, Dean Richardson at UPenns New Bolton Center, who rose to stardom in the horse world when he operated on 2006 Kentucky Derby winner Barbaro after he broke several bones in his right hind leg at the start of the Preakness Stakes, worked at Carolina Equine Clinic before he was even admitted to vet school.

I saw him when I went up for the 50th reunion and reminded him he used to plant trees for us down here, McCashin joked.

McCashin still performs some surgeries in the clinics padded operating room, but like most vets refers severe colic cases and broken limbs to N.C. State. In 40 years of veterinary practice, there has been plenty of development to keep abreast of things that dont involve picking up a scalpel.

IRAP, stem cell therapy and other regenerative therapies have replaced counter-irritating methods in treating common tendon and soft tissue injuries in horses. The telltale scars of pinfiring applying extreme heat or cold to a horses leg were once frequent markings in horses retiring from the racetrack but are now out of vogue among most trainers.

(Photo by Ted Fitzgerald/The Pilot)

You would do counterirritation just to give the horse time off, McCashin recalled.

The advent of digital imaging has made diagnosing lameness easier than ever but McCashin failed to join N.C. States faculty in their enthusiasm when the school first acquired an equine MRI system.

Its a great research tool and you can definitely learn a whole lot more by getting that kind of detail, but they get really reliant on some of that technology when they get out of school, so theyre stuck, he said. I always tell them you can use your ears and your eyes and your fingers, if you learn to use them, to discover a lot on a horse.

McCashins patients range from carbon copies of the horses he rode in his showjumping heyday to horses of a different color entirely: Standardbreds training in Pinehurst, barrel racing Quarter Horses in Carthage, and mammoth jack donkeys in Wagram.

Riding a Paso Fino in the Andes on a recent vacation to Peru, it was all he could do not to conduct an impromptu study of the hardy horses respiration rates at varying elevation levels.

When you really love doing the kind of work you do, its hard to retire, he said. Its hard to give that up. You like to be selective in what you do and what you dont do. Ive had surgeries to repair this and repair that, my back, and then I had my heart ablated for a-fib, so I just try not to get sedentary.

Follow this link:
After 50 Years, Equine Vet Not Ready for the Pasture - Southern Pines Pilot

Read More...

State looks to WSU for elk hoof disease research – goskagit.com

July 5th, 2017 8:42 pm

The state Department of Fish & Wildlife continues to investigate the cause and spread of a hoof disease affecting elk in the state, including in Skagit County.

The disease is caused by a bacteria that can cause hoof deformities. The bacteria is known to also cause lameness in affected livestock.

Its spread into northwest Washington remains a mystery, as the disease was first found in southwest parts of the state years earlier.

Story continues below video

In late 2015, an elk with the disease was found on Highway 20 in Skagit County. In 2016, two elk north of the Whatcom-Skagit county line were also found to have the disease.

A new state law directs Fish & Wildlife and Washington State University to continue researching how the disease spreads between animals and from one location to another.

The law was sponsored by Sen. Kirk Pearson, R-Monroe, who chairs the Senate Natural Resources and Parks Committee.

The law takes effect July 21. The recently passed state budget includes about $1.5 million toward the laws goals.

The law directs the WSU College of Veterinary Medicine to monitor elk herds, identify causes for the spread of the disease and come up with solutions to prevent it.

Pearson said in a news release that action is needed because livestock farmers have expressed fear of the disease affecting their herds.

WSUs College of Veterinary Medicine has long been a partner in the states work on the issue, including having six representatives on Fish & Wildlifes Technical Advisory Group for the elk hoof disease, said Fish & Wildlife statewide elk specialist Brock Hoenes.

WSU College of Veterinary Medicine spokesman Charlie Powell said the universitys Washington Animal Disease Diagnostic Laboratory received several elk hooves from Fish & Wildlife leading up to the diagnosis of the hoof disease.

We dont need to see any more hooves ... We have moved into the next step of needing to do comprehensive research, he said.

With the law set to take effect and funding secured, the university will likely designate a faculty member to oversee elk hoof disease research and to dedicate some staff to handle experiments, Powell said.

Fish & Wildlife veterinarian Kristin Mansfield said beyond knowing that the disease is at least in part caused by an infectious bacteria, many questions remain.

Questions that need answers include whether the bacteria can persist in the environment, how the disease is passed from one elk to another, how the disease affects elk survival and population sizes, where in the state the disease is being seen and whether some elk have a genetic resistance to it.

WSU is one of several universities and government labs Fish & Wildlife has collaborated with on research about the disease.

Mansfield said WSUs work helped diagnose the disease.

They had a key role in the early years starting in about 2009, when the disease first emerged in the landscape in elk in southwest Washington, she said. We collected several samples from elk in those early years and the majority of those samples went to WSU, so they played a key role in helping us diagnose what the disease was.

Masnsfield said along with work at U.S. Department of Agriculture labs, the University of Liverpool and other locations, WSU can continue helping to reveal more information about the hoof disease.

Meanwhile, Fish & Wildlife continues to seek public reports of hoof deformities in elk killed in collisions, killed by hunters or observed limping.

Hoenes said reports have helped Fish & Wildlife confirm the disease in Skagit, Whatcom, Thurston and Mason counties in recent years.

Skagit County residents have reported seeing one or more limping elk in September and December 2015, March and August 2016, and March 2017.

Those are a handful of the 1,100 reports Fish & Wildlife has received statewide since it started taking online reports in 2012.

I really feel for people who are seeing this out there in the wild, said Powell, who has also received calls from distressed members of the public who have seen elk with deformed hooves.

See the article here:
State looks to WSU for elk hoof disease research - goskagit.com

Read More...

Kidney disease: how could stem cells help? | Eurostemcell

July 5th, 2017 8:41 pm

The kidneys are towards the back of the body, roughly 10 cm above the hipbones and just below the ribcage. They are the bodys filtering units, maintaining a safe balance of fluid, minerals, salts and other substances in the blood. They produce urine to remove waste and harmful substances from the body. They also produce several hormones: erythropoietin (EPO), which acts on the bone marrow to increase the production of red blood cells; calcitriol (active Vitamin D3), which promotes absorption and use of calcium and phosphate for healthy bones and teeth; and the enzyme renin, which is involved in monitoring and controlling blood pressure.

The key working component of the kidney is the nephron.

The nephron - the functional unit of the kidney:The best evidence so far for stem cells in the adult kidney suggests they might be found in the blue area, called the urinary pole.

The nephron is made up of:

Microscope image of kidney tissue showing tubules. One tubule is highlighted to show epithelial cells (blue), cell nuclei (green) and the tubule lumen (dark center).

See the article here:
Kidney disease: how could stem cells help? | Eurostemcell

Read More...

UW-Madison scientists, inspired by old bones, find new strategy for … – Madison.com

July 5th, 2017 8:41 pm

Protein-based drugs are increasingly used to treat bone disorders, kidney disease, wounds, arthritis and cancer. But the proteins frequently degrade, limiting their therapeutic potential and sometimes causing immune reactions.

UW-Madison scientists, inspired by proteins found intact in centuries-old human bones, created a mineral coating that mimics bone and appears to keep proteins stable.

Whats needed is a delivery system that remains localized, releases the protein over an extended time frame and keeps the protein active, said William Murphy, a UW-Madison professor of biomedical engineering.

Murphy and his colleagues, including Xiaohua Yu of the UW School of Medicine and Public Health, reported on their mineral coating constructed at the miniature level of biology known as the nanoscale in this weeks edition of the journal Advanced Materials.

In a lab dish, the mineral coating released a protein, called basic fibroblast growth factor, which remained active for more than a month. When the protein was released by a commonly used system made with polymers, or plastics and rubber, it stayed active for less than a week.

In rabbits, the scientists repaired Achilles tendon tears by stitching together the severed portions of the tendon. Sutures lined with mineral coating that released two growth factors healed the injury better than regular sutures, Murphy said.

Even after the mineral coatings were subject to harmful solvents in the lab dish and sterilization of the sutures conditions that can cause proteins to degenerate the proteins remained intact.

We really can hit these proteins with a sledgehammer, so to speak, and they remain protected by the mineral coating, Murphy said.

Murphy and his colleagues knew about archaeological discoveries of growth factors and other proteins preserved in human teeth and bones from the Middle Ages. But it was a 2010 report about DNA extracted from a 19,000-year-old emu eggshell in Australia that really gave him the idea for medical applications.

It triggered a greater interest in how powerful these calcified tissues can be for stabilizing biologic molecules, said Murphy, co-director of UW-Madisons Stem Cell and Regenerative Medicine Center. If we could recreate some critical aspects of mineralized tissues, they may serve as a template for protein stabilization.

He and his team created the coating by soaking a special surface in a solution containing mineral ions found in human blood, and growing crystals. Its not all that different from a really simple crystal growth kit that a grammar school student might buy, he said.

The scientists are now using the mineral coating in rodent studies of protein therapies for rheumatoid arthritis.

Other applications could include knee and hip implants and drugs for cancer, wounds and bone disorders. The system might also help improve drugs such as erythropoietin, or EPO, used to boost red blood cells damaged by kidney disease. The drugs unstable proteins can cause immune system reactions.

If proteins could be better stabilized in drug delivery, patients might need injections only once every month or two instead of every day or week, Murphy said.

Originally posted here:
UW-Madison scientists, inspired by old bones, find new strategy for ... - Madison.com

Read More...

Benefit to assist former Litchfield paramedic – Crow River Media

July 5th, 2017 8:41 pm

Knowing hes helped many people in times of medical crises, friends and family of Jesse Wadsworth want to lift up the former Litchfield EMT/paramedic in his own time of need.

Wadsworth was diagnosed with multiple myeloma, a rare bone marrow cancer, in mid-May. A former Willmar resident who recently moved to Clara City, he has worked as an EMT/paramedic in Meeker and Stearns counties for 18 years, including 13 years in Litchfield.

Wadsworth started as an EMT in Litchfield in 2003. He became a paramedic in 2008 and served as a captain for Gold Cross Ambulance in Litchfield from 2012 to 2016.

Wadsworth and his family wife, Carrie, and sons, Ben, 19, Blake, 15, and Matthew, 11 have made the Willmar area their home for the past 18 years.

Family and friends have organized a benefit dinner and silent auction, set for July 28, at the Spicer American Legion (155 Lake Ave. N.) A suggested donation of $10 will be accepted for the meal, and drinks will be available.

After his cancer diagnosis May 17, Wadsworth immediately began intraveneous and oral chemotherapy, according to his sister, Misty Maher, who is helping organize the benefit. On May 23, he was admitted to Mayo Clinic in Rochester for two weeks due to kidney failure. Along with chemotherapy, he began plasmapharisis (similar to dialysis) and blood transfusions due to anemia.

Wadsworth continues to travel weekly to Mayo Clinic for chemotherapy treatments. In a few months, after he concludes chemotherapy treatment, he will begin to receive stem cell transplants. He will be confined to a clean room at the Mayo hospital for weeks at a time, Maher said.

Wadsworth is the familys primary financial provider, but due to the serious nature of his condition and the medical treatment it necessitates, he is unable to work at this time, Maher said.

Wadsworths wife is his primary caregiver and travels with him to each appointment, staying until his release.

Maher said funds raised at the benefit will assist with medical expenses, but, just as important, she hopes his friends, family, present and past colleagues and the communities hes served will gather around him and lift him up with support, giving and prayer to help ease a burden and feel surrounded by love during this difficult time.

Maher said donations for the benefit groceries for dinner, dcor, silent auction items and cash or gift certificates are appreciated. To volunteer or to donate, contact Maher at 320-262-1498 or Wadsworths sister-in-law, Nickie Johnson, at 304-790-4668.

Read the original post:
Benefit to assist former Litchfield paramedic - Crow River Media

Read More...

Omeros: Next Big Thing In Biotech – Seeking Alpha

July 5th, 2017 8:41 pm

Omeros Corporation (OMER) is a biopharmaceutical company which develops and commercialize both small-molecule and protein therapeutics for the treatment of inflammation, coagulopathies and disorders of the central nervous system. Omeros has one of the most diverse pipelines and recently emerged as a strong investment target. The company has one marketed product and four drug candidates in clinical stage with various others in preclinical stage in their pipeline. A company with 12 drug candidate under development in their clinical and pre clinical pipeline has lot of potential and could turn out to be a company with blockbuster portent in the next couple of years.

Omeros first marketed product Omidria, a 1% phenylephrine and 0.3% ketorolac injection is a part of its proprietary PharmacoSurgery platform. It is primarily designed to prevent the intraoperative miosis (pupil constriction) during cataract surgery or intraocular lens (IOL) replacement and to reduce postoperative ocular pain. The main benefit from Omidria is that it prevents damage to the ocular structures, especially the iris, during surgery as a result of smaller pupil size.

Omidria is a pupil dilator that helps eye surgeons operate on lenses with fewer complications. In 2016, Omidria generated over $41 million in total sales, and in Q1 2017, it generated $12.3 million in sales. At present, nearly 3 million cataract surgeries are performed each year in the U.S. alone and assuming that it works better than any other traditional method of maintaining pupil dilation during surgery, this drug has billion dollar potential.

The pipeline for Omeros is diverse and quite extensive. OMS721 is the lead product candidate most likely to hit the market next. Currently, OMS721 is being tested in three areas; atypical hemolytic uremic syndrome (aHUS, which is a rare life threatening disorder resulting in blood clot throughout the body), hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA, a disorder triggered by stem cell transplant surgery), and immunoglobulin A nephropathy (IGAN, a disease where IgA antibodies build up in the kidneys leading to inflammation and possible kidney failure). OMS721 for treating Atypical Hemolytic Uremic Syndrome is already in the Phase 3 stage.

OMS721 is a human monoclonal antibody targeting a protein called "MASP-2.", which when inhibited can help prevent damaging immune reactions seen in the above disorders. OMS721 recently received the breakthrough therapy designation from the FDA for treating IgA Nephropathy and other renal diseases. FDAs breakthrough therapy designation enables expedited development and review of a drug candidate for the treatment of a serious or life-threatening disease. Proteinuria (uACR) is an important marker for disease progression in patients with IgA nephropathy, and improvement in proteinuria is associated with improved clinical outcomes. The company announced positive data from its Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders, including IgA nephropathy. As reported for the three patients who completed treatment, mean improvement in uACR values was 76% and mean decrease in 24-hour urine protein levels was 66%. Concurrently, daily steroid doses for all patients were substantially reduced or completely eliminated.

Omeros also is pursuing accelerated approval for OMS721 in aHUS. The FDA has already granted fast track designation for OMS721 in patients with aHUS and orphan designation for OMS721 in patients with complement-mediated TMAs, including aHUS and HSCT-TMA. The potential of the lead pipeline candidate OMS721 of Omeros seems to be even more exciting than Omidrias. Its lead clinical-stage candidate OMS721 has shown positive data from Phase 2 clinical trials in both renal disorders and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). If the results achieved in small and mid-stage clinical trials can be repeated in late-stage studies, which are currently underway, Omeros could have a second drug with $1 billion per year sales potential.

A success from the company's first drug, and encouraging clinical trial results from the lead product candidate OMS721 which is in late-stage development, has produced strong movements in the company stock in the recent past. It gained close to 150 percent this year. The company has multiple drugs in its pipeline, which means that the company needs to have a steady cash flow to ensure that the development work is carried out without any hindrance.

The company has several upcoming catalysts as it progresses with the clinical trial of its lead drug candidates . The companys lead product candidate OMS721 is in Phase 3. Any positive news on this candidate will help propel the stock further. Omeros Corporation's market cap has more than doubled this year to about $1 billion but there is plenty of potential still left. If Omidria and OMS721 continue on their success to blockbuster status, the stock could give huge incentives over the next couple of years.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Excerpt from:
Omeros: Next Big Thing In Biotech - Seeking Alpha

Read More...

Smelling your food makes you fat | Berkeley News – UC Berkeley

July 5th, 2017 8:40 pm

iStock photo

Our sense of smell is key to the enjoyment of food, so it may be no surprise that in experiments at the University of California, Berkeley, obese mice who lost their sense of smell also lost weight.

Whats weird, however, is that these slimmed-down but smell-deficient mice ate the same amount of fatty food as mice that retained their sense of smell and ballooned to twice their normal weight.

In addition, mice with a boosted sense of smell super-smellers got even fatter on a high-fat diet than did mice with normal smell.

The findings suggest that the odor of what we eat may play an important role in how the body deals with calories. If you cant smell your food, you may burn it rather than store it.

These results point to a key connection between the olfactory or smell system and regions of the brain that regulate metabolism, in particular the hypothalamus, though the neural circuits are still unknown.

This paper is one of the first studies that really shows if we manipulate olfactory inputs we can actually alter how the brain perceives energy balance, and how the brain regulates energy balance, said Cline Riera, a former UC Berkeley postdoctoral fellow now at Cedars-Sinai Medical Center in Los Angeles.

Humans who lose their sense of smell because of age, injury or diseases such as Parkinsons often become anorexic, but the cause has been unclear because loss of pleasure in eating also leads to depression, which itself can cause loss of appetite.

The new study, published this week in the journal Cell Metabolism, implies that the loss of smell itself plays a role, and suggests possible interventions for those who have lost their smell as well as those having trouble losing weight.

Sensory systems play a role in metabolism. Weight gain isnt purely a measure of the calories taken in; its also related to how those calories are perceived, said senior author Andrew Dillin, the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research, professor of molecular and cell biology and Howard Hughes Medical Institute Investigator. If we can validate this in humans, perhaps we can actually make a drug that doesnt interfere with smell but still blocks that metabolic circuitry. That would be amazing.

Riera noted that mice as well as humans are more sensitive to smells when they are hungry than after theyve eaten, so perhaps the lack of smell tricks the body into thinking it has already eaten. While searching for food, the body stores calories in case its unsuccessful. Once food is secured, the body feels free to burn it.

After UC Berkeley researchers temporarily eliminated the sense of smell in the mouse on the bottom, it remained a normal weight while eating a high-fat diet. The mouse on the top, which retained its sense of smell, ballooned in weighton the same high-fat diet.

The smell-deficient mice rapidly burned calories by up-regulating their sympathetic nervous system, which is known to increase fat burning. The mice turned their beige fat cells the subcutaneous fat storage cells that accumulate around our thighs and midriffs into brown fat cells, which burn fatty acids to produce heat. Some turned almost all of their beige fat into brown fat, becoming lean, mean burning machines.

In these mice, white fat cells the storage cells that cluster around our internal organs and are associated with poor health outcomes also shrank in size.

The obese mice, which had also developed glucose intolerance a condition that leads to diabetes not only lost weight on a high-fat diet, but regained normal glucose tolerance.

On the negative side, the loss of smell was accompanied by a large increase in levels of the hormone noradrenaline, which is a stress response tied to the sympathetic nervous system. In humans, such a sustained rise in this hormone could lead to a heart attack.

Though it would be a drastic step to eliminate smell in humans wanting to lose weight, Dillin noted, it might be a viable alternative for the morbidly obese contemplating stomach stapling or bariatric surgery, even with the increased noradrenaline.

For that small group of people, you could wipe out their smell for maybe six months and then let the olfactory neurons grow back, after theyve got their metabolic program rewired, Dillin said.

Dillin and Riera developed two different techniques to temporarily block the sense of smell in adult mice. In one, they genetically engineered mice to express a diphtheria receptor in their olfactory neurons, which reach from the noses odor receptors to the olfactory center in the brain. When diphtheria toxin was sprayed into their nose, the neurons died, rendering the mice smell-deficient until the stem cells regenerated them.

Separately, they also engineered a benign virus to carry the receptor into olfactory cells only via inhalation. Diphtheria toxin again knocked out their sense of smell for about three weeks.

In both cases, the smell-deficient mice ate as much of the high-fat food as did the mice that could still smell. But while the smell-deficient mice gained at most 10 percent more weight, going from 25-30 grams to 33 grams, the normal mice gained about 100 percent of their normal weight, ballooning up to 60 grams. For the former, insulin sensitivity and response to glucose both of which are disrupted in metabolic disorders like obesity remained normal.

Mice that were already obese lost weight after their smell was knocked out, slimming down to the size of normal mice while still eating a high-fat diet. These mice lost only fat weight, with no effect on muscle, organ or bone mass.

The UC Berkeley researchers then teamed up with colleagues in Germany who have a strain of mice that are supersmellers, with more acute olfactory nerves, and discovered that they gained more weight on a standard diet than did normal mice.

People with eating disorders sometimes have a hard time controlling how much food they are eating and they have a lot of cravings, Riera said. We think olfactory neurons are very important for controlling pleasure of food and if we have a way to modulate this pathway, we might be able to block cravings in these people and help them with managing their food intake.

Co-authors of the paper are Jens Brning, director of the Max Planck Institute for Metabolism Research in Cologne, Germany, and his colleagues Eva Tsaousidou, Linda Engstrm Ruud, Jens Alber, Hella Brnneke and Brigitte Hampel; Jonathan Halloran, Courtney Anderson and Andreas Stahl of UC Berkeley; Patricia Follett and Carlos Daniel de Magalhaes Filho of the Salk Institute for Biological Studies in La Jolla, California; and Oliver Hahn of the Max Planck Institute for Biology of Ageing in Cologne.

The work was supported by the Howard Hughes Medical Institute, the Glenn Center for Research on Aging and the American Diabetes Association.

RELATED INFORMATION

Originally posted here:
Smelling your food makes you fat | Berkeley News - UC Berkeley

Read More...

US Stem Cell Inc (OTCMKTS:USRM) is Back on Our Radar – The Oracle Dispatch

July 5th, 2017 8:40 pm

US Stem Cell Inc (OTCMKTS:USRM)has been gaining back some of its loss from last month. It might be that the markets are starting to focus on the science of USRM and not the less than healthy financials.

USRM bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. USRMs discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

US Stem Cell Inc (OTCMKTS:USRM)is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

You can find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Market are yet to react to the companys most recent news, which symboilizes a major step forward for US Stem Cell in terms of validation of its lead technology and the primary application of this technology to the healthcare space.

Specifically, the news details the publication of a preclinical trial of US Stem Cells osteoarthritis treatment. The science that underpins this treatment is pretty much the same across the whole spectrum of different target indications and thats why this validation is so important.

Essentially, the company removes fat cells from the patient through liposuction and then extracts stem cells from this removed fat. It then injects the stem cells (directly) into the region of the body for which the patient requires treatment.

USRM just recently released results from a study where stem cell treatment was injected into patients knees and patients were asked to walk for 6 minutes after the WOMAC test. The treatment numbers proved to be successful.

Across the ten patients, average WOMAC reduced to 52 at 3 months, 46 at 6 months, 42 at 1 year, 38 at 1.5 years, and 41 at 2 years. This is after one round of treatment. All of these reductions were statistically significant, recorded at p-values of 0.01 or less. Similarly, the treatment resulted in an improvement in the 6MWD test at 3 and 6 months and 1, 1.5, and 2 years post treatment.

The study is not enough to validate the treatment in total, but if the upcoming tests continue to validate this treatment, the stock could take a run.

US Stem Cell Inc (OTCMKTS:USRM) has great science and cash to burn for the moment after a $5 million financing but investors need watch out for dilution. USRM is carrying a $17.56 million market cap and 335.43 million shares outstanding. We will be watching news on this company and if the therapy results are promising again, the market may not ignore it for a second time. However, as all investors know, biotech is a risky endeavor, regardless. For continuing coverage on shares of $USRM stock, as well as other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!

Go here to read the rest:
US Stem Cell Inc (OTCMKTS:USRM) is Back on Our Radar - The Oracle Dispatch

Read More...

Global Cell Therapy Report 2017 – Technologies, Markets and Companies 2016-2026 with Profiles of Key Companies … – PR Newswire UK (press release)

July 5th, 2017 8:40 pm

DUBLIN, July 5, 2017 /PRNewswire/ --

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2016, and projected to 2026. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 306 of these are profiled in part II of the report along with tabulation of 291 alliances. Of these companies, 170 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 64 Tables and 22 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Key Topics Covered:

Part I: Technologies, Ethics & Regulations

Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit https://www.researchandmarkets.com/research/hpj9sh/cell_therapy

Source: Jain PharmaBiotech

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original post:
Global Cell Therapy Report 2017 - Technologies, Markets and Companies 2016-2026 with Profiles of Key Companies ... - PR Newswire UK (press release)

Read More...

Prominent diabetes researcher chosen to lead A. Alfred Taubman Medical Research Institute – University of Michigan Health System News (press release)

July 5th, 2017 8:40 pm

ANN ARBOR, Mich. Diabetes and obesity researcher Charles Burant, M.D., Ph.D., has been named the new director of the A. Alfred Taubman Medical Research Institute at Michigan Medicine.

He succeeds distinguished neurology professor Eva Feldman, M.D., Ph.D., who for 10 years served as founding director of the A. Alfred Taubman Medical Research Institute, the only organization of its kind created expressly to support medical doctors who also perform research in the quest for new treatments and cures.

Through the gift of A. Alfred Taubman and the generous contributions of others, the Institute has created a community of scholars who work collaboratively to advance discovery in many medical fields.

Burant is Michigan Medicines Robert C. and Veronica Atkins Professor of Metabolism endowed chair, and professor of internal medicine in the department of Metabolism, Endocrinology, and Diabetes. He also is a professor of Molecular and Integrative Physiology in the U-M Medical School, as well as in the U-M Schools of Public Health and Kinesiology.

Burant developed and is director of the Michigan Metabolomics and Obesity Center, which provides infrastructure and expertise for researchers across the country to perform basic and clinical research in metabolism, obesity and diabetes. His personal research program studies how individual differences inmetabolism affect longevity and risk for metabolic diseases, spanning the range from basic to translational to clinical research.

Charles Burant, M.D., Ph.D.

Dr. Burant will be instrumental in implementing the strategies and priorities of the Taubman Institute. His broad expertise, experience in creating collaborative research teams, and commitment to discovery and innovation will help propel the Taubman Institute to new heights in research discovery to advance the understanding of health and disease, leading to new medical treatments, says Marschall S. Runge, M.D., Ph.D., dean of the U-M Medical School, and executive vice president for medical affairs at the University of Michigan.

We remain very grateful to the Taubman family for their continued support to make new discoveries possible.

Burant earned his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carolina in Charleston. He then completed a residency at the University of California, San Francisco, and a fellowship in endocrinology at the University of Chicago before joining the U-M faculty in 1999.

About Michigan Medicine:At Michigan Medicine, we create the future of healthcare through the discovery of new knowledge for the benefit of patients and society; educate the next generation of physicians, health professionals and scientists; and serve the health needs of our citizens. We pursue excellence every day in our three hospitals, 125 clinics and home care operations that handle more than 2.1 million outpatient visits a year. The U-M Medical School is one of the nation's biomedical research powerhouses, with total research funding of more than $470 million. More information is available at http://www.michiganmedicine.org (link is external)

Here is the original post:
Prominent diabetes researcher chosen to lead A. Alfred Taubman Medical Research Institute - University of Michigan Health System News (press release)

Read More...

Sidney Health Center announces new family medicine physician – Sidney Herald Leader

July 5th, 2017 8:40 pm

Sidney Health Center is pleased to announce the successful recruit of Lisa Rosa-R, M.D. Dr. Rosa-R joins the medical staff as a family medicine physician.

Dr. Rosa-R, who is American Board Certified in family medicine, provides a wide range of primary care services to people of all ages.

Her scope of practice includes diagnosing and treating illnesses, managing chronic conditions such as high blood pressure, diabetes and asthma as well as providing preventive care such as routine checkups, health-risk assessments and screening tests for men, women and children.

Dr. Rosa-R has 30 years of experience in the medical field working as a family physician in the state of Georgia. The last 10 years she has incorporated integrative medicine into her scope of practice. Integrative medicine emphasizes the integration of complementary and alternative medicine approaches with conventional medicine.

Dr. Rosa-R graduated with a bachelor of science in mathematics from the University of Western Australia in Perth, Australia. She went onto become a Doctor of Medicine and Surgery at the University of Seville in Seville, Spain and then completed her residency in family practice at Saint Mary Hospital in Hoboken, N.J. as well as completing a Fellowship in Family Medicine at Bronx-Lebanon Albert Einstein College of New York, NY.

Dr. Rose-R is fluent in English and Spanish. To schedule an appointment with Dr. Rosa-R, please call her office at 406-488-2231 at the Sidney Health Center Clinic, Suite #110.

See original here:
Sidney Health Center announces new family medicine physician - Sidney Herald Leader

Read More...

Chief medical officer calls for gene testing revolution – BBC News – BBC News

July 4th, 2017 11:47 pm

BBC News
Chief medical officer calls for gene testing revolution - BBC News
BBC News
Cancer patients should be routinely offered DNA tests to help select the best treatments for them, according to England's chief medical officer. Prof Dame Sally ...
UK medical chief vows to spread 'genetics dream'Financial Times
All cancer patients should have their DNA tested to save lives, Chief Medical Officer saysTelegraph.co.uk
Cancer breakthrough: Treatment could be personalised to YOU by using your genesExpress.co.uk
Sky News -iNews -BT.com
all 25 news articles »

Continued here:
Chief medical officer calls for gene testing revolution - BBC News - BBC News

Read More...

Greater access to genetic testing needed for cancer diagnosis and treatment – Cancer Research UK

July 4th, 2017 11:47 pm

Cancer patients should have routine access to genetic testing to improve diagnosis and treatment, according to Englands chief medical officer.

Despite the UK being a world leader in genomic medicine its full potential is still not being realised, Professor Dame Sally Davies said in a new report.

This timely report from the chief medical officer showcases just how much is now possible in genomics research and care within the NHS. - Sir Harpal Kumar, Cancer Research UK

Davies urged clinicians and the Government to work together and make wider use of new genetic techniques in an attempt to improve cancer survival rates.

Genetic testing can pinpoint the faults in DNA that have led to a cancer forming. Different cancers have different faults, and these determine which treatments may or may not work.

Such testing could lead to patients being diagnosed faster and receiving more targeted or precise treatments.

Davies said that the age of precision medicine is now and that the NHS must act quickly to remain world class.

This technology has the potential to change medicine forever but we need all NHS staff, patients and the public to recognise and embrace its huge potential. said Davies.

Sir Harpal Kumar, Cancer Research UKs chief executive, agreed, saying that it would be a disservice to patients if the UK were slow to respond to innovations in this area.

The report recommends that within 5 years training should be available to current and future clinicians and that all patients should be being offered genomic tests just as readily as theyre given MRI scans today.

Davies also called for research and international collaboration to be prioritised, along with investment in research and services so that patients across the country have equal access.

However the report recognises potential challenges such as data protection issues and attitudes of clinicians and the public.

This timely report from the chief medical officer showcases just how much is now possible in genomics research and care within the NHS, added Sir Kumar.

Cancer Research UK is determined to streamline research, to find the right clinical trial for cancer patients and to ensure laboratory discoveries benefit patients.

And the design of clinical trials are starting to change. A number of trials are underway, like Cancer Research UKs National Lung Matrix Trial with AstraZeneca and Pfizer, where patients with a certain type of lung cancer are assigned a specific treatment based on the genetic makeup of their cancer.

However, Sir Harpal Kumar stressed that to bring the reports vision to life the Government, the NHS, regulators and research funders need to act together.

View original post here:
Greater access to genetic testing needed for cancer diagnosis and treatment - Cancer Research UK

Read More...

Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

July 4th, 2017 11:47 pm

July 3, 2017 by Ryan O'hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: "The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one."

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies's, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

"One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells," said Professor Mitchell. "We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells."

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

"In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung," explained Professor Mitchell. "This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery."

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to ...

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for ...

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

(Medical Xpress) -- Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive ...

(Phys.org)One of the most promising microscale power sources for portable and wearable electronics is a micro-supercapacitorthey can be made thin, lightweight, highly flexible, and with a high power density. Normally, ...

An international research team that includes University of Central Florida Professor Enrique del Barco, Damien Thompson of the University of Limerick and Christian A. Nijhuis of the National University of Singapore has cracked ...

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

The possibility of looking inside silicon chips to see their tiny working parts, without damaging the chips, is a step closer thanks to an international team led by scientists at the LCN.

Science fiction is full of fanciful devices that allow light to interact forcefully with matter, from light sabers to photon-drive rockets. In recent years, science has begun to catch up; some results hint at interesting ...

Dialysis, in the most general sense, is the process by which molecules filter out of one solution, by diffusing through a membrane, into a more dilute solution. Outside of hemodialysis, which removes waste from blood, scientists ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
Nano-sized drug carriers could be the future for patients with lung disease - Phys.Org

Read More...

UVa researchers working on lung transplants get $8.6M boost – The Daily Progress

July 4th, 2017 11:47 pm

Lung transplants are difficult and risky. Only about 20 percent of organ donors have lungs that are usable; just over half of those patients fortunate enough to receive a donation survive through five years.

Researchers at the University of Virginia think they can improve outcomes for lung transplant patients. The university recently received more than $8.6 million in federal grants for a series of projects meant to take on the problem on multiple fronts.

Dr. Irving Kron and Victor Laubach are spearheading research into ex-vivo lung perfusion, or the use of therapy to rehabilitate donor lungs that may be considered unsuitable because of a donors medical conditions or complications during transportation of the organ.

Lungs are especially sensitive, said Laubach, a molecular physiologist at UVa, and the lungs of most multi-organ donors cant be used because they are badly damaged when the brain is deprived of oxygen. By attaching the donor lungs to a ventilator and treating it with drugs to prevent inflammatory injury and infections, doctors can make lungs suitable for transplants.

We are using that platform to treat those lungs to recondition them and improve their chances of becoming transplantable, Laubach said. If we do that, well significantly increase the donor pool.

Researchers at UVa envision the Medical Center becoming a hub for donor lungs that can be treated and made suitable for transplants.

Dr. Christine Lau is leading a trial of the anti-inflammatory drug regadenoson commonly used in stress tests in heart patients on donor lungs. Experiments on animals have shown that when the drug is pumped into lungs prior to a transplant, it reduces the patients inflammatory response one of the main causes of injury in patients.

[A transplant] causes your immune and inflammatory system to be up in arms, Lau said. What this drug does is shuts down those reactions.

Participation in the trial is completely mandatory, Lau said, but she estimates that more than 90 percent of lung transplant patients at UVa would be eligible for it.

Dr. Sasha Krupnicks research focuses on the patients specifically on suppressing the immune cells that attack the transplanted lung that are less harmful than the current approach.

Currently, transplant patients receive a cocktail of drugs that suppress the entire immune system, putting them at higher risk of infection. Krupnick is experimenting with the use of cells or antibodies that focus on the problem actors in a patients immune system.

What weve discovered is that when we transplant an organ, theres a certain cell population that infiltrates the organ and produce nitric oxide, Krupnick said. If harnessed in the right way, they can kill the harmful T cells.

Ideally, patients would receive an injection before the procedure, reducing the need for drug treatments afterward. Most patients would be off the drug regimen 10 days after the transplant, Krupnick said.

UVa researchers also are hoping to prevent the injuries that go undetected immediately after lung transplant surgery. Many patients go one to two years after the procedure before showing signs of reperfusion injuries, which are typically caused by the bodys rejection of the new organ.

The tools surgeons currently have are fairly crude; it comes down to a chest X-ray, Laubach said. This new grant we have is going to enable us to use new imaging probes.

Using SPECT (short for single photon emission tomography) imaging, doctors should be able to detect these problems and intervene more quickly, which could save lives, Laubach said.

Laubachs team also is planning to use imaging to look at the causes of these injuries, and to get a better understanding of why the body so often rejects transplants.

By looking at all phases of the lung transplant process, UVa researchers are hoping they can make it less difficult for surgeons and less risky for patients. It will take a team effort to make that happen, Laubach said.

We have probably one of the best lung transplant research programs in the country, if not the best, he said. The collaborations have allowed this to happen.

Read this article:
UVa researchers working on lung transplants get $8.6M boost - The Daily Progress

Read More...

Noxxon/MSD start testing of immunoncologic combo – European Biotechnology

July 4th, 2017 11:45 pm

Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.

The study conducted at the National Center for Tumor Diseases in Heidelberg (Germany) will investigate the impact of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumors. In addition, Noxxon and Merck & Co will assess safety and efficacy of NOX-A12 in combination with Keytruda (pembrolizumab), Merck & Co./MSDs programmed death receptor-1 (PD-1) immune checkpoint-blocking antibody drug.

The open-label trial (NCT03168139) is composed of two parts: patients will receive NOX-A12 monotherapy for two weeks, followed by combination therapy of NOX-A12 plus pembrolizumab for up to two years. 20 patients will be enroled: 10 patients for each metastatic pancreas and colorectal cancer.

The design of the clinical trial was a collaborative effort between NOXXON and MSD. Part 1 of the study, in which patients will receive NOX-A12 monotherapy for up to two weeks, will evaluate immune infiltrate changes within the tumor microenvironment induced by CXCL12 inhibition with NOX-A12 by comparing pre- and post-treatment biopsy specimens as well as the safety and tolerability of NOX-A12 in patients with metastatic (stage IV) colorectal and pancreatic cancer. Part 2 of the study, in which NOX-A12 is to be combined with Keytruda, will assess the safety and tolerability of the combination in addition to the efficacy of treatment. Top-line data for all 20 patients from part 1 is expected to be available in Q2/2018, and initial response-rate data in Q4/2018.

NOX-A12 inhibits CXCL12, a key tumor microenvironment chemokine and a stem cell migration factor. The chemokine that acts by binding to to CXCR4 and CXCR7 may be a key partner for a wide range of IO (immuno-oncology) agents. Noxxon has generated promising pre-clinical and clinical data, including animal data showing synergy with a checkpoint inhibitor, as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The company said that its study will position the drug to be combined with multiple classes of IO approaches including those acting on or through T cells and/or NK cells.

Read the original post:
Noxxon/MSD start testing of immunoncologic combo - European Biotechnology

Read More...

Page 1,001«..1020..1,0001,0011,0021,003..1,0101,020..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick